The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway

Overview

Journal CNS Drugs

Specialties Neurology
Pharmacology

Date 2017 May 26

PMID 28540646

Citations 12

Authors

Lin Li

Affiliations

Soon will be listed here.

Abstract

The mechanistic target of rapamycin (mTOR) is an important molecule that connects aging, lifespan, energy balance, glucose and lipid metabolism, and neurodegeneration. Rapamycin exerts effects in numerous biological activities via its target protein, playing a key role in energy balance, regulation of autophagy, extension of lifespan, immunosuppression, and protection against neurodegeneration. There are many similar pathophysiological processes and molecular pathways between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM), and pharmacologic agents used to treat T2DM, including glucagon-like peptide-1 (GLP-1) analogs, seem to be beneficial for AD. mTOR mediates the effects of GLP-1 analogs in the treatment of T2DM; hence, I hypothesize that mTOR is a key molecule for mediating the protective effects of GLP-1 for AD.

Citing Articles

A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies.

Tipa R, Balan D, Georgescu M, Ignat L, Vacaroiu I, Georgescu D Int J Mol Sci. 2024; 25(9).

PMID: 38732190 PMC: 11084700. DOI: 10.3390/ijms25094972.

Cornerstone Cellular Pathways for Metabolic Disorders and Diabetes Mellitus: Non-Coding RNAs, Wnt Signaling, and AMPK.

Maiese K Cells. 2023; 12(22).

PMID: 37998330 PMC: 10670256. DOI: 10.3390/cells12222595.

Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress.

Liu D, Zhao C, Wei X, Ma Y, Wu J Parkinsons Dis. 2022; 2022:6813017.

PMID: 35873704 PMC: 9300292. DOI: 10.1155/2022/6813017.

The interplay between oxidative stress and autophagy: focus on the development of neurological diseases.

Talebi M, Mohammadi Vadoud S, Haratian A, Talebi M, Farkhondeh T, Pourbagher-Shahri A Behav Brain Funct. 2022; 18(1):3.

PMID: 35093121 PMC: 8799983. DOI: 10.1186/s12993-022-00187-3.

Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration.

Querfurth H, Lee H Mol Neurodegener. 2021; 16(1):44.

PMID: 34215308 PMC: 8252260. DOI: 10.1186/s13024-021-00428-5.

References

de la Monte S, Re E, Longato L, Tong M . Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease. J Alzheimers Dis. 2012; 30 Suppl 2:S217-29. PMC: 4562691. DOI: 10.3233/JAD-2012-111728. View

Shingo A, Kanabayashi T, Kito S, Murase T . Intracerebroventricular administration of an insulin analogue recovers STZ-induced cognitive decline in rats. Behav Brain Res. 2012; 241:105-11. DOI: 10.1016/j.bbr.2012.12.005. View

Kimura R, Okouchi M, Fujioka H, Ichiyanagi A, Ryuge F, Mizuno T . Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience. 2009; 162(4):1212-9. DOI: 10.1016/j.neuroscience.2009.05.025. View

Zhu Y, Wang J . Wogonin increases β-amyloid clearance and inhibits tau phosphorylation via inhibition of mammalian target of rapamycin: potential drug to treat Alzheimer's disease. Neurol Sci. 2015; 36(7):1181-8. DOI: 10.1007/s10072-015-2070-z. View

Chen Y, Tian Z, Liang Z, Sun S, Dai C, Lee M . Brain gene expression of a sporadic (icv-STZ Mouse) and a familial mouse model (3xTg-AD mouse) of Alzheimer's disease. PLoS One. 2012; 7(12):e51432. PMC: 3517562. DOI: 10.1371/journal.pone.0051432. View

Santos R, Correia S, Cardoso S, Carvalho C, Santos M, Moreira P . Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease. J Neurochem. 2011; 117(6):927-36. DOI: 10.1111/j.1471-4159.2011.07262.x. View

Pandini G, Pace V, Copani A, Squatrito S, Milardi D, Vigneri R . Insulin has multiple antiamyloidogenic effects on human neuronal cells. Endocrinology. 2012; 154(1):375-87. DOI: 10.1210/en.2012-1661. View

Kunz J, Henriquez R, Schneider U, Movva N, Hall M . Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell. 1993; 73(3):585-96. DOI: 10.1016/0092-8674(93)90144-f. View

Khanfar M, AbuKhader M, Alqtaishat S, Taha M . Pharmacophore modeling, homology modeling, and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalol, glyburide, metipranolol, sulfamethizole, glipizide, and pioglitazone. J Mol Graph Model. 2013; 42:39-49. DOI: 10.1016/j.jmgm.2013.02.009. View

10.

Harman D . The free radical theory of aging. Antioxid Redox Signal. 2003; 5(5):557-61. DOI: 10.1089/152308603770310202. View

11.

Hurtado-Carneiro V, Sanz C, Roncero I, Vazquez P, Blazquez E, Alvarez E . Glucagon-like peptide 1 (GLP-1) can reverse AMP-activated protein kinase (AMPK) and S6 kinase (P70S6K) activities induced by fluctuations in glucose levels in hypothalamic areas involved in feeding behaviour. Mol Neurobiol. 2012; 45(2):348-61. DOI: 10.1007/s12035-012-8239-z. View

12.

Mori H, Inoki K, Opland D, Munzberg H, Villanueva E, Faouzi M . Critical roles for the TSC-mTOR pathway in β-cell function. Am J Physiol Endocrinol Metab. 2009; 297(5):E1013-22. PMC: 2781354. DOI: 10.1152/ajpendo.00262.2009. View

13.

Wang F, Guo X, Shen X, Kream R, Mantione K, Stefano G . Vascular dysfunction associated with type 2 diabetes and Alzheimer's disease: a potential etiological linkage. Med Sci Monit Basic Res. 2014; 20:118-29. PMC: 4138067. DOI: 10.12659/MSMBR.891278. View

14.

Avruch J, Long X, Ortiz-Vega S, Rapley J, Papageorgiou A, Dai N . Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab. 2008; 296(4):E592-602. PMC: 2670622. DOI: 10.1152/ajpendo.90645.2008. View

15.

Choi K, Kim S, Ha J, Kim S, Son J . A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death. J Neurochem. 2009; 112(2):366-76. DOI: 10.1111/j.1471-4159.2009.06463.x. View

16.

Alagiakrishnan K, Sankaralingam S, Ghosh M, Mereu L, Senior P . Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease. Discov Med. 2013; 16(90):277-86. View

17.

Chatterjee S, Peters S, Woodward M, Mejia Arango S, Batty G, Beckett N . Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia. Diabetes Care. 2015; 39(2):300-7. PMC: 4722942. DOI: 10.2337/dc15-1588. View

18.

Lafay-Chebassier C, Perault-Pochat M, Page G, Rioux Bilan A, Damjanac M, Pain S . The immunosuppressant rapamycin exacerbates neurotoxicity of Abeta peptide. J Neurosci Res. 2006; 84(6):1323-34. DOI: 10.1002/jnr.21039. View

19.

Li X, Alafuzoff I, Soininen H, Winblad B, Pei J . Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J. 2005; 272(16):4211-20. DOI: 10.1111/j.1742-4658.2005.04833.x. View

20.

Crane P, Walker R, Hubbard R, Li G, Nathan D, Zheng H . Glucose levels and risk of dementia. N Engl J Med. 2013; 369(6):540-8. PMC: 3955123. DOI: 10.1056/NEJMoa1215740. View